title: Optimization of intranasal corticosteroid formulations for the treatment of allergic rhinitis.
abstract: Intranasal corticosteroids (INCSs) provide safe and effective treatment of allergic rhinitis (AR). Currently available INCSs differ in terms of the components included in each formulation that may influence efficacy, tolerability, and patient preference for treatment. Patient preference for a specific INCS is largely attributable to the sensory attributes that are dependent on characteristics of the formulation. Preservatives and additives can irritate and dry the mucosal membranes, or they can confer an unpleasant odor or taste to an INCS formulation. Spray volume also may affect patients' sensory perceptions of INCS formulations. Relative osmotic pressure or tonicity may affect nasal absorption and retention of an INCS and potentially affect clinical efficacy. A hypotonic suspension is a new formulation option for INCSs that may improve sensory attributes and has the potential to improve patient satisfaction and treatment outcomes in patients with AR. Optimization of INCS formulations may improve efficacy and tolerability and influence patient preference for treatment.
authors.affiliation: Altana Pharma US, 220 Park Avenue, Florham Park, NJ 07932, USA. mark.wingertzahn@altanapharma-us.com
authors.forename: Mark A
authors.initials: MA
authors.lastname: Wingertzahn
authors.forename: M Jennifer
authors.initials: MJ
authors.lastname: Derebery
authors.forename: Harold S
authors.initials: HS
authors.lastname: Nelson
mesh_terms: D000281:Administration, Intranasal; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004304:Dosage Forms; D006801:Humans; D006889:Hydroxycorticosteroids / Q000008:administration & dosage* / Q000009:adverse effects; D017060:Patient Satisfaction; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D004304:Dosage Forms; D006889:Hydroxycorticosteroids